October 19, 2020 -- Oncopeptides has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for OPD5, a second drug candidate based on its proprietary peptide drug conjugate platform.
OPD5 is based on a proprietary platform that leverages aminopeptidases to release alkylating agents rapidly into tumor cells.
The company plans to initiate clinical development of OPD5 with an open label phase I dose escalation study on the safety and efficacy of OPD5 as a myeloablative regimen followed by autologous stem cell transplantation in patients with relapsed refractory multiple myeloma.
The first drug that Oncopetides has initiated regulatory activities for is melflufen.
Copyright © 2020 scienceboard.net